New hope for tough leukemia: Three-Drug combo trial launches
NCT ID NCT06621212
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs—mitoxantrone liposome, cytarabine, and venetoclax—in 72 adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if this combo can help more patients achieve complete remission. Participants will receive the drugs in cycles and be monitored for response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mitoxantrone hydrochloride liposome, cytarabine, and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia that has returned or not responded to prior therapy.
What could go wrong
This is an early phase 2 study with only 72 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact